Advertisement
Corrigendum Free access | 10.1172/JCI179917
Find articles by D’Avola, A. in: JCI | PubMed | Google Scholar
Find articles by Legrave, N. in: JCI | PubMed | Google Scholar
Find articles by Tajan, M. in: JCI | PubMed | Google Scholar
Find articles by Chakravarty, P. in: JCI | PubMed | Google Scholar
Find articles by Shearer, R. in: JCI | PubMed | Google Scholar
Find articles by
King, H.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by Kluckova, K. in: JCI | PubMed | Google Scholar
Find articles by Cheung, E. in: JCI | PubMed | Google Scholar
Find articles by
Clear, A.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by
Gunawan, A.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by Zhang, L. in: JCI | PubMed | Google Scholar
Find articles by
James, L.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by
MacRae, J.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by Gribben, J. in: JCI | PubMed | Google Scholar
Find articles by
Calado, D.
in:
JCI
|
PubMed
|
Google Scholar
|
Find articles by Vousden, K. in: JCI | PubMed | Google Scholar
Find articles by Riches, J. in: JCI | PubMed | Google Scholar
Published February 15, 2024 - More info
The synthesis of serine from glucose is a key metabolic pathway supporting cellular proliferation in healthy and malignant cells. Despite this, the role that this aspect of metabolism plays in germinal center biology and pathology is not known. Here, we performed a comprehensive characterization of the role of the serine synthesis pathway in germinal center B cells and lymphomas derived from these cells. We demonstrate that upregulation of a functional serine synthesis pathway is a metabolic hallmark of B cell activation and the germinal center reaction. Inhibition of phosphoglycerate dehydrogenase (PHGDH), the first and rate-limiting enzyme in this pathway, led to defective germinal formation and impaired high-affinity antibody production. In addition, overexpression of enzymes involved in serine synthesis was a characteristic of germinal center B cell–derived lymphomas, with high levels of expression being predictive of reduced overall survival in diffuse large B cell lymphoma. Inhibition of PHGDH induced apoptosis in lymphoma cells, reducing disease progression. These findings establish PHGDH as a critical player in humoral immunity and a clinically relevant target in lymphoma.
Annalisa D’Avola, Nathalie Legrave, Mylène Tajan, Probir Chakravarty, Ryan L. Shearer, Hamish W. King, Katarina Kluckova, Eric C. Cheung, Andrew J. Clear, Arief S. Gunawan, Lingling Zhang, Louisa K. James, James I. MacRae, John G. Gribben, Dinis P. Calado, Karen H. Vousden, John C. Riches
Original citation: J Clin Invest. 2022;132(9):e153436. https://doi.org/10.1172/JCI153436
Citation for this corrigendum: J Clin Invest. 2024;134(4):e179917. https://doi.org/10.1172/JCI179917
In Figure 6A, the label for the SUDHL4 cell line was incorrect. In Figure 7G, the photographs for the 7- and 14-day time points were switched. The correct figure parts are below.
The authors regret the errors.
See the related article at PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.